Indications Semaglutide is a prescription GLP-1 receptor agonist indicated: As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a body mass index (BMI) 30 kg/m (obesity), or 27 kg/m (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia)
[1][2] Dziaanie leku Mounjaro Dziaanie leku Mounjaro (tirzepatydu) rni si od klasycznych lekw z jednej grupy inkretynowej, poniewa jest to agonista dwch receptorw: receptorw GIP oraz GLP-1
doi: 10.1172/jci.insight.133429 26 Barreto-ViannaARCAguilaMBMandarim-de-LacerdaCA
It has been estimated that 12% of the US population has had exposure to a GLP-1RA and 6% are currently using one 11
Doing so alleviates trial and error, ensuring precision medicine thats more personalized than ever This innovation may prove especially handy when it comes to compounded Semaglutide Therapy, given how some patients can react adversely to the medicine